Premium
Verapamil and Nifedipine in Combination for the Treatment of Hypertension
Author(s) -
Kaesemeyer W. H.,
Carr A. A.,
Bottini P. B.,
Prisant L. M.
Publication year - 1994
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1994.tb03965.x
Subject(s) - nifedipine , verapamil , medicine , dihydropyridine , blood pressure , adverse effect , anesthesia , rash , cardiology , calcium
The authors examined the efficacy and safety of the combination of verapamil and nifedipine in the control of hypertension. Retrospective analysis of blood pressures was obtained on 50 patients who had historically documented essential hypertension and were receiving verapamil and nifedipine. The patients had moderate to severe hypertension; 27 of 50 (54%) were uncontrolled on prescribed regimens of two or more separate classes of drugs. Control was defined by the ability to maintain a blood pressure of ≤ 160/90 by providing doses of verapamil (max: 480 mg/day) and nifedipine (max: 180 mg/day). Twenty‐nine (50%) were black and 21 (42%) were white. Ages ranged from 16 to 84 years. Mean duration of therapy was 1–2 years. Only 3 of 50 (6%) were control failures after providing verapamil and nifedipine. Three of 50 (6%) were discontinued because of side effects — reversible hepatitis (2) and rash (1). There were no serious adverse events, i.e., CHF or arrhythmias. Manageable ankle edema was seen in 14 of 50 (28%) patients. Verapamil and nifedipine, a combination of a dihydropyridine and a non‐dihydropyridine calcium antagonist, was effective and safe in this group of patients with difficult‐to‐manage hypertension.